{"id":"W2792666902","doi":"10.1056/nejmoa1713976","title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Neutropenia; Leukemia; Gastroenterology; Immunology; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001434805,0.0002953556,0.0009532692,0.0002302264,0.0001749549,0.0003293197,0.0003668039,0.0004618587,0.001970539],"category_scores_gemma":[0.001270265,0.0001235189,0.0005067137,0.0003256401,0.0003956826,0.0002649457,0.0001702772,0.0009430912,0.0001757357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000501293,"about_ca_system_score_gemma":0.0005119296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004788052,"about_ca_topic_score_gemma":0.001274579,"domain_scores_codex":[0.9994086,0.000401704,0.00003328092,0.00006561047,0.00004650341,0.00004439956],"domain_scores_gemma":[0.9990609,0.0004676508,0.0002439162,0.00004621573,0.00002620022,0.0001550938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6269493,0.008497022,0.01627217,0.002149788,0.001771193,0.00033428,0.0002418443,0.002800499,0.01482153,0.0005678438,0.002284339,0.3233101],"study_design_scores_gemma":[0.6852775,0.2579869,0.04073714,0.0003270552,0.001102807,0.001107591,0.00007213061,0.002213513,0.002531672,0.0006139205,0.007994977,0.00003477353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842505,0.01397001,0.0001903395,0.0001787981,0.00006196304,0.0002761763,0.00008867495,0.00001959077,0.0009638371],"genre_scores_gemma":[0.9955864,0.002939357,0.0004951567,0.0001938605,0.00009852014,0.0002253078,0.0001514863,0.000003388919,0.0003065651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001970539,"threshold_uncertainty_score":0.007588029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03256968068832229,"score_gpt":0.3346197826151289,"score_spread":0.3020501019268066,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}